肢端肥大症合并高泌乳素血症患者的基础与临床研究
|
摘要
目的
肢端肥大症是一种发病率比较低的疾病,它的特点是血清中生长激素(GH)和胰岛素样生长因子1(IGF-1)的含量增高。尽管肢端肥大症的病程进展比较缓慢,但它可导致全身各个系统的改变,尤其是面容和肢体末梢的变化。由于肢端肥大症可引起心、脑血管及肺部并发症,因而,患者的发病率和死亡率要高于正常人群。一般来说,大多数肢端肥大症患者都是由生长激素腺瘤引起的,他们所表现出的症状体征也都是由血液中过高的生长激素引起的；而且,在肢端肥大症患者中,大约有16-27%的病人最终发展为肢端肥大症合并高泌乳素血症,即患者血清中生长激素和泌乳素(PRL)同时升高。由于生长激素合并高泌乳素血症患者的发病率相对较低,所以,到目前为止,此类患者还没有比较完整的临床研究资料。本研究的主要目的在于通过比较单纯生长激素增高的肢端肥大症患者与肢端肥大症合并高泌乳素血症患者的临床资料,来揭示生长激素合并高泌乳素血症患者的临床特点。
方法
第一部分患者术前临床特点
回顾性分析2002.01至2010.06期间在山东省立医院神经外科就诊的生长激素及泌乳素腺瘤的患者。其中,279例患者具有完整的术前及术后一年的临床资料。所有患者均在我院接受经鼻蝶入路垂体瘤切除术治疗,并且保留比较完整的临床资料。所有患者都接受了术前MRI检查。根据患者术前血清生长激素和泌乳素的水平,患者分为GH组(单纯GH升高的患者)和GH+PRL组(GH与PRL均升高的患者)。为了研究GH+PRL患者的PRL水平,选取部分泌乳素腺瘤患者作为PRL组。所有患者均在术前、术后3天、3月和术后12月进行GH和PRL测定。在治疗和随访期间,我们主要观察了患者的临床表现、激素水平、免疫组化结果以及MRI表现方面的改变,借此来研究生长激素腺瘤合并高泌乳素血症患者的临床特点和影响手术效果的因素。
第二部分：标本处理
所有组织标本均先用10%福尔马林溶液进行固定,然后用石蜡包埋,最后用苏木精进行染色处理。所有标本均用GH和PRL抗体进行检测。
结果
第一部分：临床特点
在GH组,男性占50.5%,患者的平均发病年龄为45.6±13.9岁(11.4-75.2岁),从开始发病到就诊的平均间隔时间为66.0±65.3月(0.5-324月),肿瘤平均最大直径为2.2±0.9cm(0.6-4.2cm)。在GH+PRL组,男性占42.3%,患者的平均发病年龄为40.4±11.4岁(20.1-72.6岁),平均间隔时间为52.8±49.4月(1.0-240月),肿瘤平均最大直径为2.6±1.1cm(0.5-5.8cm)。两组患者在平均发病年龄(P=0.001)和肿瘤平均最大直径(P=0.004)方面有明显的差异,但在性别比例(P=0.209)和发病间隔(P=0.067)上两者无明显差异。
患者最常见的临床表现为面容改变、手脚增大、头痛、头晕、恶心呕吐、易疲劳及手脚麻木,常见的并发症为高血压和糖尿病。由垂体内分泌功能紊乱引起的常见临床表现为多饮多尿、性欲减退,在女性还表现为月经紊乱和溢乳。在这些临床表现中,头痛、头晕、恶心呕吐、肢端麻木、性欲减退以及易疲劳的发病率在两组患者中没有明显的差异,但在面容改变、多饮多尿、手脚增大、月经紊乱和溢乳上,两者差异明显。在并发症方面,糖尿病的发病率差异明显。数据表明,GH组患者的面容改变、多饮多尿、手脚增大和糖尿病的发病比例较高,但在女性患者中,月经紊乱和溢乳的发病率明显要低。
第二部分：激素水平的比较
GH组患者术前GH和PRL水平分别为42.35±30.48ng/ml和15.21±12.26ng/ml.GH+PRL组患者的GH和PRL水平分别为23.43±15.78ng/ml和131.29±76.62ng/ml.与GH+PRL组相比,GH组患者的GH水平明显偏高(P<0.001),但PRL水平明显偏低(P<0.001)。术后,除了GH组患者的PRL水平无明显变化外,两组患者的激素水平均明显下降。GH组患者术后3天的GH水平为20.37±18.31ng/ml,术后1年的水平为23.87±20.01ng/ml,两者之间无明显差别。在GH+PRL组,患者术后3天、术后1年的GH水平分别为13.61±10.86ng/ml和14.84±11.62ng/ml；在相同时间点上,PRL的水平分别为32.96±15.91ng/ml和33.44±15.38ng/ml。而且,术后各时间点的GH和PRL之间没有明显差异。但是,不论是GH还是PRL,两种激素的术前、术后水平均存在明显的差异。PRL组患者术前PRL水平为169.2±92.0ng/ml,术后3天、1年的PRL水平分别为45.4±30.5ng/ml和42.9±34.8ng/ml。
第三部分：免疫组化结果
GH组患者GH和PRL免疫组化的阳性率分别为91.2%和30.7%。GH+PRL组患者GH和PRL免疫组化的阳性率分别为84.5%和86.6%。所以,两组患者的PRL阳性率差别明显。而且,进一步的分析后发现,GH和PRL免疫组化的阳性率与术前激素水平没有明显的相关性(r=+0.348,P>0.05和r=+0.457,P>0.05)。
第四部分：MRI结果分析
在GH和GH+PRL组,术前大中腺瘤患者的比例分别为60.4%和45.1%,两组患者差异明显(P=0.041)。根据术后三个月的MRI检查结果分析,GH组患者肿瘤切除率(全切及次全切)为80.7%,GH+PRL组的切除率为69.1%,两者差异明显(P=0.037)。
第五部分：复发率
通过分析术后1年的激素和MRI检查结果,我们发现,GH和GH+PRL组的肿瘤复发率分别为7.1%和11.3%,两者之间没有明显的差别(P=0.185)。
结论
1.与单纯GH升高的生长激素腺瘤患者相比,GH+PRL患者具有发病年龄早、典型外貌特征少,但肿瘤直径较大的特点。特别是在女性患者,生长激素合并高泌乳素血症患者的月经紊乱和溢乳的发病率明显增高。
2. GH+PRL患者的生长激素水平相对较低,但泌乳素水平明显偏高。GH+PRL患者的PRL免疫组化阳性率高,但GH阳性率与单纯GH患者相比无明显差别。而且,免疫组化阳性率与术前激素水平没有明显的相关性。
3. GH+PRL患者肿瘤的全切及次全切率比单纯GH患者低,但二者复发率无明显差别。
Objective
Acromegaly is a rare disease characterized by excess secretion of growth hormone (GH) and increased circulating concentrations of insulin-like growth factor-1(IGF-1). It is characterized by slowly progressive acquired somatic disfigurement (mainly involving face and extremities) and systemic manifestations. The disease is associated with increased morbidity and premature mortality, due to cardiovascular, cerebrovascular, or respiratory causes. In general, the underlying abnormality in most cases is hypersecretion of GH by the pituitary GH-producing tumors. Nonetheless, about16-27%of these patients have increased GH and prolactin (PRL) levels. Therefore, the characteristics of acromegaly with increased growth hormone (GH) and hyperprolactinemia in patients were not clearly established, probably due to the relatively low annual incidence. The aim of this study is to evaluate clinical data from a large cohort of acromegalic patients with and without hyperprolactinemia.
Design and methods
Part1. patients and their characteristics before surgery
A retrospective chart review was performed on all patients with GH producing adenomas treated between January2002and June2010at the Department of Neurosurgery, Provincial Hospital Affiliated to Shandong University, Jinan. A total of279patients had a complete set of data before and one year after surgery. Magnetic resonance imaging (MRI) examinations were done in all patients. Based on the preoperative GH and PRL levels, patients were classified as follows:GH group (acromegalic patients with elevated GH levels), GH+PRL group (acromegalic patients with both elevated GH and prolactin levels) and PRL group (patients with prolactinoma). GH and PRL levels were assessed before surgery and3days and12months after surgery respectively. A stabilization or a further improvement of postoperative changes in clinical, hormonal, immunohistochemical and magnetic resonance imaging (MRI) parameters was observed in all patients throughout the follow-up period.
Part2. immunohistochemistry examination
All specimens were fixed in10%formalin, embedded in paraffin and stained by the haematoxylin-eosin method. All the resected tissues were examined by immunohistochemistry with antibodies against GH and PRL.
Results
Part1. Clinical features before surgery
In GH group,50.5%of the patients were male; the mean age at diagnosis was45.6±13.9years (range,11.4-75.2years). The mean time interval from the onset of acromegaly-specific symptoms and signs to the date of diagnosis was66.0±65.3months (range,0.5-324months). The mean maximal diameter of adenomas was2.2±0.9cm (range,0.6-4.2cm). In GH+PRL group,42.3%of the patients were male; the mean age at diagnosis, the mean time interval and the mean maximal diameter of adenomas were40.4±11.4years (range,20.1-72.6years),52.8±49.4months (range,1.0-240months) and2.6±1.1cm (range,0.5-5.8cm) respectively. The mean age at diagnosis and mean maximal diameter of adenomas were significantly different between the two groups (P=0.001and P=0.004, respectively), but gender and the mean time interval had no significant differences.
The most common presenting clinical manifestations and complications encountered in the two groups (GH group vs. GH+PRL group) were coarse facial features (75.4%vs.54.3%), large hands and feet (73.8%vs.58.6%), headache (38.5%vs.41.9%), dizziness (10.0%vs.10.1%), nausea and vomiting (4.6%vs.3.9%), fatigue (3.8%vs.3.9%), distension and numbness (3.8%vs.1.6%), hypertension (10.0%vs.3.9%), diabetes mellitus (17.7%vs.6.9%) and those of pituitary endocrinological disturbances:polyuria and polydipsia (16.2%vs.5.4%), hyposexuality (4.6%vs.10.9%), and in females, menstrual disorder (13.8%vs.54.3%) and galactorrhea (3.1%vs.22.4%). No significant differences were observed in headache (P=0.613), dizziness (P=1.0), nausea and vomiting (P=1.0), hyposexuality (P=0.066), distension and numbness (P=0.447), fatigue (P=1.0) and hypertension (P=0.085). But there were significant differences between the two groups:coarse facial features (P=0.013), polyuria and polydipsia (P=0.008), large hands and feet (P<0.001), menstrual disorder (P<0.001), galactorrhea (P<0.001) and diabetes mellitus (P=0.013). So, data indicated that there were higher incidences of coarse facial features, polyuria and polydipsia, large hands and feet and diabetes mellitus in GH group patients, but the incidences of menstrual disorder and galactorrhea in female patients were especially lower than that of GH+PRL group.
Part2. Comparison of hormone levels
The levels of GH and PRL in GH group before surgery were42.35±30.48ng/ml and15.21±12.26ng/ml, while those in GH+PRL group were23.43±15.78ng/ml and131.29±76.62ng/ml respectively. Therefore, the GH level of GH group was significantly higher than that of GH+PRL group (P<0.001), whereas the PRL was extremely lower (P<0.001). The GH and PRL levels of the two groups decreased obviously after surgery, except the PRL of GH group. The GH levels of GH group were20.37±18.31ng/ml at3days,19.26±18.22ng/ml at3months and23.87±20.01ng/ml at12months after the operation, and there were no significant differences with each other (P=0.526). In GH+PRL group, the postoperative levels of GH at the three time points were13.61±10.86ng/ml,13.22±11.52ng/ml and14.84±11.62ng/ml respectively, while those of PRL were32.96±15.91ng/ml, 31.82±17.63ng/ml and33.44±15.38ng/ml respectively. Also, both the postoperative GH and PRL levels in GH+PRL group had no significant differences with each other (P=0.584and P=0.778, respectively). However, there were significant differences when the postoperative levels of GH or PRL were compared between two groups. Moreover, except the PRL of GH group, there were also significant differences when pre-and postoperative levels of GH or PRL were compared (P<0.01,P<0.01and P<0.01,respectively). The preoperative PRL level was169.2±92.0ng/ml, and the postoperative PRL levels were45.4±30.5ng/ml at3days and42.9±34.8ng/ml at12months.
Part3. Immunohistochemistry evaluation
It showed that the positive rates of GH and PRL in GH group were91.2%and30.7%, and those results of GH+PRL group were84.5%and86.6%respectively. So, significant difference was observed between the PRL positive rates of the two groups (P<0.05), whereas GH, as expected, did not (P=0.11). Moreover, there is no significant correlation between the preoperative mean GH or PRL concentrations and the immunostaining positive rates (r=+0.348, P>0.05and r=+0.457, P>0.05, respectively).
Part4. MRI findings
The proportion of preoperative meso-and macro-adenoma of GH+PRL group was significantly higher than that of GH group (60.4%vs.45.1%, P=0.041). According to the MRI findings at3-month after surgery, the overall resection rate of GH+PRL group was distinctly lower than that of GH group (69.1%vs.80.7%, P=0.037).
Part5. recurrence rate
Hormone and MRI examinations were performed on all patients12-month after surgery. By analyzing these data, we found the recurrence rates of GH and GH+PRL group were7.1%and11.3%, and no significant difference was observed between the two groups (P=0.185).
Conclusions
1. Compared to patients with merely GH-secreting adenomas, acromegalic patients with hyperprolactinemia are characterized by an earlier onset of disease, lesser acromegalic features, lower GH levels, but larger tumor sizes, whereas in female patients, GH-prolactin secreting adenomas are associated with higher incidences of menstrual disorders and galactorrhea.
2. Compared to patients with merely GH-secreting adenomas, acromegalic patients with hyperprolactinemia have lower GH but higher PRL levels and higher PRL but normal GH positive rates. Moreover, no significant correlations between the preoperative mean GH or PRL concentrations and the immunostaining positive rates were observed.
3. Compared to patients with merely GH-secreting adenomas, the resection rate is lower in acromegalic patients with hyperprolactinemia, but there is no significant differences in recurrence rate between these patients.
肢端肥大症是一种发病率比较低的疾病,它的特点是血清中生长激素(GH)和胰岛素样生长因子1(IGF-1)的含量增高。尽管肢端肥大症的病程进展比较缓慢,但它可导致全身各个系统的改变,尤其是面容和肢体末梢的变化。由于肢端肥大症可引起心、脑血管及肺部并发症,因而,患者的发病率和死亡率要高于正常人群。一般来说,大多数肢端肥大症患者都是由生长激素腺瘤引起的,他们所表现出的症状体征也都是由血液中过高的生长激素引起的；而且,在肢端肥大症患者中,大约有16-27%的病人最终发展为肢端肥大症合并高泌乳素血症,即患者血清中生长激素和泌乳素(PRL)同时升高。由于生长激素合并高泌乳素血症患者的发病率相对较低,所以,到目前为止,此类患者还没有比较完整的临床研究资料。本研究的主要目的在于通过比较单纯生长激素增高的肢端肥大症患者与肢端肥大症合并高泌乳素血症患者的临床资料,来揭示生长激素合并高泌乳素血症患者的临床特点。
方法
第一部分患者术前临床特点
回顾性分析2002.01至2010.06期间在山东省立医院神经外科就诊的生长激素及泌乳素腺瘤的患者。其中,279例患者具有完整的术前及术后一年的临床资料。所有患者均在我院接受经鼻蝶入路垂体瘤切除术治疗,并且保留比较完整的临床资料。所有患者都接受了术前MRI检查。根据患者术前血清生长激素和泌乳素的水平,患者分为GH组(单纯GH升高的患者)和GH+PRL组(GH与PRL均升高的患者)。为了研究GH+PRL患者的PRL水平,选取部分泌乳素腺瘤患者作为PRL组。所有患者均在术前、术后3天、3月和术后12月进行GH和PRL测定。在治疗和随访期间,我们主要观察了患者的临床表现、激素水平、免疫组化结果以及MRI表现方面的改变,借此来研究生长激素腺瘤合并高泌乳素血症患者的临床特点和影响手术效果的因素。
第二部分：标本处理
所有组织标本均先用10%福尔马林溶液进行固定,然后用石蜡包埋,最后用苏木精进行染色处理。所有标本均用GH和PRL抗体进行检测。
结果
第一部分：临床特点
在GH组,男性占50.5%,患者的平均发病年龄为45.6±13.9岁(11.4-75.2岁),从开始发病到就诊的平均间隔时间为66.0±65.3月(0.5-324月),肿瘤平均最大直径为2.2±0.9cm(0.6-4.2cm)。在GH+PRL组,男性占42.3%,患者的平均发病年龄为40.4±11.4岁(20.1-72.6岁),平均间隔时间为52.8±49.4月(1.0-240月),肿瘤平均最大直径为2.6±1.1cm(0.5-5.8cm)。两组患者在平均发病年龄(P=0.001)和肿瘤平均最大直径(P=0.004)方面有明显的差异,但在性别比例(P=0.209)和发病间隔(P=0.067)上两者无明显差异。
患者最常见的临床表现为面容改变、手脚增大、头痛、头晕、恶心呕吐、易疲劳及手脚麻木,常见的并发症为高血压和糖尿病。由垂体内分泌功能紊乱引起的常见临床表现为多饮多尿、性欲减退,在女性还表现为月经紊乱和溢乳。在这些临床表现中,头痛、头晕、恶心呕吐、肢端麻木、性欲减退以及易疲劳的发病率在两组患者中没有明显的差异,但在面容改变、多饮多尿、手脚增大、月经紊乱和溢乳上,两者差异明显。在并发症方面,糖尿病的发病率差异明显。数据表明,GH组患者的面容改变、多饮多尿、手脚增大和糖尿病的发病比例较高,但在女性患者中,月经紊乱和溢乳的发病率明显要低。
第二部分：激素水平的比较
GH组患者术前GH和PRL水平分别为42.35±30.48ng/ml和15.21±12.26ng/ml.GH+PRL组患者的GH和PRL水平分别为23.43±15.78ng/ml和131.29±76.62ng/ml.与GH+PRL组相比,GH组患者的GH水平明显偏高(P<0.001),但PRL水平明显偏低(P<0.001)。术后,除了GH组患者的PRL水平无明显变化外,两组患者的激素水平均明显下降。GH组患者术后3天的GH水平为20.37±18.31ng/ml,术后1年的水平为23.87±20.01ng/ml,两者之间无明显差别。在GH+PRL组,患者术后3天、术后1年的GH水平分别为13.61±10.86ng/ml和14.84±11.62ng/ml；在相同时间点上,PRL的水平分别为32.96±15.91ng/ml和33.44±15.38ng/ml。而且,术后各时间点的GH和PRL之间没有明显差异。但是,不论是GH还是PRL,两种激素的术前、术后水平均存在明显的差异。PRL组患者术前PRL水平为169.2±92.0ng/ml,术后3天、1年的PRL水平分别为45.4±30.5ng/ml和42.9±34.8ng/ml。
第三部分：免疫组化结果
GH组患者GH和PRL免疫组化的阳性率分别为91.2%和30.7%。GH+PRL组患者GH和PRL免疫组化的阳性率分别为84.5%和86.6%。所以,两组患者的PRL阳性率差别明显。而且,进一步的分析后发现,GH和PRL免疫组化的阳性率与术前激素水平没有明显的相关性(r=+0.348,P>0.05和r=+0.457,P>0.05)。
第四部分：MRI结果分析
在GH和GH+PRL组,术前大中腺瘤患者的比例分别为60.4%和45.1%,两组患者差异明显(P=0.041)。根据术后三个月的MRI检查结果分析,GH组患者肿瘤切除率(全切及次全切)为80.7%,GH+PRL组的切除率为69.1%,两者差异明显(P=0.037)。
第五部分：复发率
通过分析术后1年的激素和MRI检查结果,我们发现,GH和GH+PRL组的肿瘤复发率分别为7.1%和11.3%,两者之间没有明显的差别(P=0.185)。
结论
1.与单纯GH升高的生长激素腺瘤患者相比,GH+PRL患者具有发病年龄早、典型外貌特征少,但肿瘤直径较大的特点。特别是在女性患者,生长激素合并高泌乳素血症患者的月经紊乱和溢乳的发病率明显增高。
2. GH+PRL患者的生长激素水平相对较低,但泌乳素水平明显偏高。GH+PRL患者的PRL免疫组化阳性率高,但GH阳性率与单纯GH患者相比无明显差别。而且,免疫组化阳性率与术前激素水平没有明显的相关性。
3. GH+PRL患者肿瘤的全切及次全切率比单纯GH患者低,但二者复发率无明显差别。
Objective
Acromegaly is a rare disease characterized by excess secretion of growth hormone (GH) and increased circulating concentrations of insulin-like growth factor-1(IGF-1). It is characterized by slowly progressive acquired somatic disfigurement (mainly involving face and extremities) and systemic manifestations. The disease is associated with increased morbidity and premature mortality, due to cardiovascular, cerebrovascular, or respiratory causes. In general, the underlying abnormality in most cases is hypersecretion of GH by the pituitary GH-producing tumors. Nonetheless, about16-27%of these patients have increased GH and prolactin (PRL) levels. Therefore, the characteristics of acromegaly with increased growth hormone (GH) and hyperprolactinemia in patients were not clearly established, probably due to the relatively low annual incidence. The aim of this study is to evaluate clinical data from a large cohort of acromegalic patients with and without hyperprolactinemia.
Design and methods
Part1. patients and their characteristics before surgery
A retrospective chart review was performed on all patients with GH producing adenomas treated between January2002and June2010at the Department of Neurosurgery, Provincial Hospital Affiliated to Shandong University, Jinan. A total of279patients had a complete set of data before and one year after surgery. Magnetic resonance imaging (MRI) examinations were done in all patients. Based on the preoperative GH and PRL levels, patients were classified as follows:GH group (acromegalic patients with elevated GH levels), GH+PRL group (acromegalic patients with both elevated GH and prolactin levels) and PRL group (patients with prolactinoma). GH and PRL levels were assessed before surgery and3days and12months after surgery respectively. A stabilization or a further improvement of postoperative changes in clinical, hormonal, immunohistochemical and magnetic resonance imaging (MRI) parameters was observed in all patients throughout the follow-up period.
Part2. immunohistochemistry examination
All specimens were fixed in10%formalin, embedded in paraffin and stained by the haematoxylin-eosin method. All the resected tissues were examined by immunohistochemistry with antibodies against GH and PRL.
Results
Part1. Clinical features before surgery
In GH group,50.5%of the patients were male; the mean age at diagnosis was45.6±13.9years (range,11.4-75.2years). The mean time interval from the onset of acromegaly-specific symptoms and signs to the date of diagnosis was66.0±65.3months (range,0.5-324months). The mean maximal diameter of adenomas was2.2±0.9cm (range,0.6-4.2cm). In GH+PRL group,42.3%of the patients were male; the mean age at diagnosis, the mean time interval and the mean maximal diameter of adenomas were40.4±11.4years (range,20.1-72.6years),52.8±49.4months (range,1.0-240months) and2.6±1.1cm (range,0.5-5.8cm) respectively. The mean age at diagnosis and mean maximal diameter of adenomas were significantly different between the two groups (P=0.001and P=0.004, respectively), but gender and the mean time interval had no significant differences.
The most common presenting clinical manifestations and complications encountered in the two groups (GH group vs. GH+PRL group) were coarse facial features (75.4%vs.54.3%), large hands and feet (73.8%vs.58.6%), headache (38.5%vs.41.9%), dizziness (10.0%vs.10.1%), nausea and vomiting (4.6%vs.3.9%), fatigue (3.8%vs.3.9%), distension and numbness (3.8%vs.1.6%), hypertension (10.0%vs.3.9%), diabetes mellitus (17.7%vs.6.9%) and those of pituitary endocrinological disturbances:polyuria and polydipsia (16.2%vs.5.4%), hyposexuality (4.6%vs.10.9%), and in females, menstrual disorder (13.8%vs.54.3%) and galactorrhea (3.1%vs.22.4%). No significant differences were observed in headache (P=0.613), dizziness (P=1.0), nausea and vomiting (P=1.0), hyposexuality (P=0.066), distension and numbness (P=0.447), fatigue (P=1.0) and hypertension (P=0.085). But there were significant differences between the two groups:coarse facial features (P=0.013), polyuria and polydipsia (P=0.008), large hands and feet (P<0.001), menstrual disorder (P<0.001), galactorrhea (P<0.001) and diabetes mellitus (P=0.013). So, data indicated that there were higher incidences of coarse facial features, polyuria and polydipsia, large hands and feet and diabetes mellitus in GH group patients, but the incidences of menstrual disorder and galactorrhea in female patients were especially lower than that of GH+PRL group.
Part2. Comparison of hormone levels
The levels of GH and PRL in GH group before surgery were42.35±30.48ng/ml and15.21±12.26ng/ml, while those in GH+PRL group were23.43±15.78ng/ml and131.29±76.62ng/ml respectively. Therefore, the GH level of GH group was significantly higher than that of GH+PRL group (P<0.001), whereas the PRL was extremely lower (P<0.001). The GH and PRL levels of the two groups decreased obviously after surgery, except the PRL of GH group. The GH levels of GH group were20.37±18.31ng/ml at3days,19.26±18.22ng/ml at3months and23.87±20.01ng/ml at12months after the operation, and there were no significant differences with each other (P=0.526). In GH+PRL group, the postoperative levels of GH at the three time points were13.61±10.86ng/ml,13.22±11.52ng/ml and14.84±11.62ng/ml respectively, while those of PRL were32.96±15.91ng/ml, 31.82±17.63ng/ml and33.44±15.38ng/ml respectively. Also, both the postoperative GH and PRL levels in GH+PRL group had no significant differences with each other (P=0.584and P=0.778, respectively). However, there were significant differences when the postoperative levels of GH or PRL were compared between two groups. Moreover, except the PRL of GH group, there were also significant differences when pre-and postoperative levels of GH or PRL were compared (P<0.01,P<0.01and P<0.01,respectively). The preoperative PRL level was169.2±92.0ng/ml, and the postoperative PRL levels were45.4±30.5ng/ml at3days and42.9±34.8ng/ml at12months.
Part3. Immunohistochemistry evaluation
It showed that the positive rates of GH and PRL in GH group were91.2%and30.7%, and those results of GH+PRL group were84.5%and86.6%respectively. So, significant difference was observed between the PRL positive rates of the two groups (P<0.05), whereas GH, as expected, did not (P=0.11). Moreover, there is no significant correlation between the preoperative mean GH or PRL concentrations and the immunostaining positive rates (r=+0.348, P>0.05and r=+0.457, P>0.05, respectively).
Part4. MRI findings
The proportion of preoperative meso-and macro-adenoma of GH+PRL group was significantly higher than that of GH group (60.4%vs.45.1%, P=0.041). According to the MRI findings at3-month after surgery, the overall resection rate of GH+PRL group was distinctly lower than that of GH group (69.1%vs.80.7%, P=0.037).
Part5. recurrence rate
Hormone and MRI examinations were performed on all patients12-month after surgery. By analyzing these data, we found the recurrence rates of GH and GH+PRL group were7.1%and11.3%, and no significant difference was observed between the two groups (P=0.185).
Conclusions
1. Compared to patients with merely GH-secreting adenomas, acromegalic patients with hyperprolactinemia are characterized by an earlier onset of disease, lesser acromegalic features, lower GH levels, but larger tumor sizes, whereas in female patients, GH-prolactin secreting adenomas are associated with higher incidences of menstrual disorders and galactorrhea.
2. Compared to patients with merely GH-secreting adenomas, acromegalic patients with hyperprolactinemia have lower GH but higher PRL levels and higher PRL but normal GH positive rates. Moreover, no significant correlations between the preoperative mean GH or PRL concentrations and the immunostaining positive rates were observed.
3. Compared to patients with merely GH-secreting adenomas, the resection rate is lower in acromegalic patients with hyperprolactinemia, but there is no significant differences in recurrence rate between these patients.
引文
1中华医学会内分泌学分会,中华医学会神经外科学分会.中国肢端肥大症诊治规范(草案).中国实用内科杂志.2006 26：1772-1777.
2王曲,王任直,姚勇.垂体生长激素腺瘤的研究及治疗进展.神经疾病与精神卫生.2008 8：158-160.
3雷霆,张华楸,舒凯等.垂体生长激素腺瘤的诊断与治疗.中国现代神经疾病杂志.2005 5：4-7.
4梁丽,李成江.肢端肥大症11例并发症临床分析.中国实用内科杂志.200525：928-929.
5 Cook DM, Ezzat S, Katznelson L, et al. AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. Endocr Pract.2004 10:213-225.
6 Katznelson L, Atkinson JL, Cook DM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly--2011 update:executive summary. Endocr Pract.2011 17:636-646.
7 Chanson P, Salenave S, Kamenicky P, et al. Pituitary tumours:acromegaly. Best Pract Res Clin Endocrinol Metab.2009 10:555-574.
8 Kauppinen-Makelin R, Sane T, Reunanen A, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab.2005 90:4081-4086.
9 Krzentowska-Korek A, Golkowski F, Baldys-Waligorska A, et al. Efficacy and complications of neurosurgical treatment of acromegaly. Pituitary 2011 14:157-162.
10 Hossain B, M. Drake W. Acromegaly. Medicine 2009 37:407-410.
11 Chanson P, Salenave S, Kamenicky P, et al. Best Pract Res Clin Endocrinol Metab. 200923:555-574.
12 Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999 2:29-41.
13 Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas:a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006 91:4769-4775.
14 Schneider HJ, Sievers C, Saller B, et al. High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin Endocrinol (Oxf).200869:432-435.
15 Vasilev V, Daly A, Zacharieva S, et al. Management of acromegaly. F1000 Med Rep.20102:54.
16 Scanarini M, Mingrino S. Pituitary adenoma secreting more than two hormones. Acta Neuropathol 1979 48:67-72.
17 Schatz H, Daun M, Leicht R, et al. Immunohistochemical examination of pituitary adenomas. Hormone Res.198521:246-253.
18 Ogo A, Haji M, Natori S, et al. Acromegaly with hyperprolactinemia developed after bilateral adrenalectomy in a patient with Cushing's syndrome due to adrenocortical nodular hyperplasia. Endocr J.199340:17-25.
19 Scacchi M, Cavagnini F. Acromegaly. Pituitary 2006 9:297-303.
20 Sheppard MC. Primary medical therapy for acromegaly. Clin Endocrinol (Oxf). 2003 58:387-399.
21 Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly:a consensus statement. J Clin Endocrinol Metab.200085:526-529.
22 Bonert VS, Melmed S. Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. Nat Clin Pract Endocrinol Metab.20062:408-412.
23 Andersen M, Hagen C, Frystyk J, et al. Development of acromegaly in patients with prolactinomas. Eur J Endocrinol.2003149:17-22.
24 Nabarro JD. Acromegaly. Clin Endocrinol (Oxf).198726:481-512.
25 Ezzat S, Forster MJ, Berchtold P, et al. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore).199473:233-240.
26 Nachtigall L, Delgado A, Swearingen B, et al. Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab.2008 93: 2035-2041.
27 Alexander L, Appleton D, Hall R, et al. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf).1980 12:71-79.
28 Klijn JGM, Lamberts SWJ, de Jong FH, et al. Interrelationships between tumor size, age, plasma growth hormone and incidence of extrasellar extension in acromegalic patients. Acta Endocrinol (Copenh).198095:289-297.
29 Kauppinen-Makelin R, Sane T, Reunanen A, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab.2005 90 4081-4086.
30 Valenta LJ, Elias AN. Clinical acromegaly with undetectable growth hormone and hyperprolactinemia. J Natl Med Assoc.1987 79:555,559-560.
31 Fazio S, Cittadini A, Cuocolo A, et al. Impaired cardiac performance is a distinct feature of uncomplicated acromegaly. J Clin Endocrinol Metab.1994 79:441-446.
32 Colao A, Marzullo P, Ferone D, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab. 200085:3132-3140.
33Grunstein RR, Ho KK, Sullivan CE. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med.1994 121:478-483.
34 Colao A, Marzullo P, Vallone G, et al. Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol (Oxf).199951:611-618.
35 Reid TJ, Post KD, Bruce JN, et al. Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006:acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf).201072:203-208.
36 Serri O, Chik CL, Ur E, et al. Diagnosis and management of hyperprolactinemia. CMAJ.2003 169:575-581.
37 Lania AG, Ferrero S, Pivonello R, et al. Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. J Clin Endocrinol Metab.201095:13-17.
38 Fideleff HL, Boquete HR, Suarez MG, et al. Prolactinoma in children and adolescents. Horm Res.200972:197-205.
39 Melmed S, Braunstein GD, Horvath E, et al. Pathophysiology of acromegaly. Endocr Rev.1983 4:271-290.
40王明栋,马文斌,郭梅等.垂体生长激素腺瘤合并泌乳素腺瘤的临床病理特点及诊断治疗.中国医学科学院学报.2005 27：245-248.
41 Maheshwari HG, et al. Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma. J Clin Endocrinol Metab.2000 85:3409-3416.
42 Scheithauer BW, et al. Pathology of excessive production of growth hormone. Clin Endocrinol Metab.1986 15:655-681.
43 Clemmons DR, Van Wyk JJ, Ridgway EC, et al. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med.1979301:1138-1142.
44 Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-1/ somatomedin-C in acromegaly:correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab.198867:69-73.
45 Winer LM, Shaw MA, Baumann G. Basal plasma growth hormone levels in man: new evidence for rhythmicity of growth hormone secretion. J Clin Endocrinol Metab.199070:1678-1686.
46 Freda PU, Post KD, Powell JS, et al. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab.199883:3808-3816.
47 Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management:an update. J Clin Endocrinol Metab.200994:1509-1517.
48 Kreutzer J, Vance ML, Lopes MB, et al. Surgical management of GH- secreting pituitary adenomas:an outcome study using modern remission criteria. J Clin Endocrinol Metab.2001 86:4072-4077.
49 Biermasz NR, van Dulken H, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab.2000 85: 4596-4602.
50 Swearingen B, Barker FG Ⅱ, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab.199883:3419-3426.
51 Cappabianca P, Cavallo LM, de Divitiis E. Endoscopic endonasal transsphenoidal surgery. Neurosurgery 2004 55:933-940; discussion 940-941.
52 Shimon I, Cohen ZR, Ram Z, et al. Transsphenoidal surgery for acromegaly: endocrinological follow up of 98 patients. Neurosurgery 2001 48:1239-1243.
53 Kreutzer J, Vance ML, Lopes MB, et al. Surgical management of GH-secreting pituitary adenomas:an outcome study using modern remission criteria. J Clin Endocrinol Metab.2001 86:4072-4077.
54 Ahmed S, Elsheikh M, Stratton IM, et al. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf). 199950:561-567.
55 Laws ER, Vance ML, Thapar K. Pituitary surgery for the management of acromegaly. Horm Res.2000 53(Suppl 3):71-75.
56 Fahlbusch R, Keller B, Ganslandt O, et al. Transsphenoidal surgery in acromegaly investigated by intraoperative high-field magnetic resonance imaging. Eur J Endocrinol.2005 153:239-248.
57 Melmed S. Medical progress:acromegaly. N Engl J Med.2006 355:2558-2573.
58 Fahlbusch R, Keller B, Ganslandt O, et al. Transsphenoidal surgery in acromegaly investigated by intraoperative high-field magnetic resonance imaging. Eur J Endocrinol.2005 153:239-248.
59 Schwartz TH, Stieg PE, Anand VK. Endoscopic transsphenoidal pituitary surgery with intraoperative magnetic resonance imaging. Neurosurgery 2006 58(1 Suppl):ONS 44-51.
60 Jho HD. Endoscopic transsphenoidal surgery. J Neurooncol.200154:187-195.
61 Swearingen B, Barker FG Ⅱ, Katznelson L, et al. Longterm mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab.199883:3419-3426.
62 Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab.2004 89:667-674.
63 Dimaraki EV, Jaffe CA, DeMott-Friberg R, et al. Acromegaly with apparently normal GH secretion:implications for diagnosis and follow-up. J Clin Endocrinol Metab.2002 87:3537-3542.
64 Gittoes NJ, Sheppard MC, Johnson AP, et al. Outcome of surgery for acromegaly-the experience of a dedicated pituitary surgeon. QJM.1999 92:741-745.
65 Clayton RN. How many surgeons to operate on acromegalic patients? Clin Endocrinol (Oxf).199950:557-559.
66 Clayton RN, Stewart PM, Shalet SM, et al. Pituitary surgery for acromegaly: should be done by specialists. BMJ.1999319:588-589.
67 Ciric I, Ragin A, Baumgartner C, et al. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 1997 40:225-236.
68 Colao A, Ferone D, Lastoria S, et al. Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab.199681:2356-2362.
69 Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly:results of a multicenter trial in 103 patients- a clinical research center study. J Clin Endocrinol Metab.199580:2768-2775.
70 Ben-Shlomo A, Melmed S. Clinical review 154:the role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab. 2003 88:963-968.
71 Jho HD. Endoscopic transsphenoidal surgery. J Neurooncol.2001 54:187-195.
72 Cappabianca P, Cavallo LM, Colao A, et al. Endoscopic endonasal transsphenoidal approach:outcome analysis of 100 consecutive procedures. Minim Invasive Neurosurg.200245:193-200.
73 Cappabianca P, de Divitiis E. Image guided endoscopic transnasal removal of recurrent pituitary adenomas. Neurosurgery 2003 52:483-484.
74 Bohinski RJ, Warnick RE, Gaskill-Shipley MF, et al. Intraoperative magnetic resonance imaging to determine the extent of resection of pituitary macroadenomas during transsphenoidal microsurgery. Neurosurgery 2001 49: 1133-1143.
75 Fahlbusch R, Ganslandt O, Buchfelder M, et al. Intraoperative magnetic resonance imaging during transsphenoidal surgery. J Neurosurg.200195:381-390.
76 Kreutzer J, Vance ML, Lopes M.B, et al. Surgical management of GH-secreting pituitary adenomas:an outcome study using modern remission criteria. J Clin Endocrinol Metab.2001 86:4072-4077.
77 Shimon I., Cohen Z.R., Ram Z, et al. Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery 2001 48:1239-1243; discussion 1244-1245.
78 Jenkins PJ, Bates P, Carson MN, et al. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-1 in patients with acromegaly. J Clin Endocrinol Metab.200691:1239-1245.
79顾昌伟,孙青芳,卞留贯.垂体生长激素腺瘤治疗现状及预后分析.中国微侵袭神经外科杂志.2008 13：90-93.
80 Barkan AL, Halasz I, Dornfeld KJ et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor 1 in patients with acromegaly. J Clin Endocrinol Metab.199782:3187-3191.
81 Biermasz NR, van Dulken H, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab.200085:2476-2482.
82 Barrande G, Pittino-Lungo M, Coste J et al. Hormonal and metabolic effects of radiotherapy in acromegaly:long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab.200085:3779-3785.
83 Brada M, Burchell L, Ashley S et al. The incidence of cerebrovascular accidents in patients with pituitary adenoma. Int J Radiat Oncol Biol Phys.1999 45: 693-698.
84 Mahmoud-Ahmed AS, Suh JH, Mayberg MR. Gamma knife radiosurgery in the management of patients with acromegaly:a review. Pituitary 20014:223-230.
85 Attanasio R, Epaminonda P, Motti E, et al. Gamma-knife radiosurgery in acromegaly:a 4-year follow-up study. J Clin Endocrinol Metab.2003 88: 3105-3112.
86 Castinetti F, Taieb D, Kuhn JM, et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly:correlation with initial hypersecretion. J Clin Endocrinol Metab.200590:4483-4488.
87毕智勇,于春江.肢端肥大症的治疗进展.国外医学神经病学神经外科学分册.2004 31：159-163.
88王志勇,雷霆.肢端肥大症的综合治疗.实用医学杂志.2006 22：1467-1468.
89 Jaffe, CA, Barkan, A.L. Treatment of acromegaly with dopamine agonists. Endocrinol. Metab. Clin. North Am.1992 21:713-735.
90 Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly:a study in 64 patients. J Clin Endocrinol Metab.199883:374-378.
91张正善,丁学华.垂体生长激素腺瘤的治疗进展.中国微侵袭神经外科杂志.2005 10：233-235.
92 Vance, M.L.,Harris, A.G. Longterm treatment of 189 acromegalic patients with the somatostatin analog octreotide. Arch. Intern. Med.1991 151:1573-1578.
93 Newman, CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly:results of a multicenter trial in 103 patients- a clinical research center study. J Clin Endocrinol Metab.1993 80:2768-2775.
94 Grass P, Marbach P, Bruns C, et al. Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly:pharmacokinetic and pharmacodynamic relationships. Metabolism 1996 45:27-30.
95 Stewart, PM, Kane KF, Stewart SE, et al. Depot long-acting somatostatin analog (Sandostatin LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab.1995 80:3267-3272.
96 Lancranjan I, Atkinson AB. Results of a European multicentre study with sandostatin LAR in acromegalic patients. Pituitary 1999 1:105-114.
97 Heron I, Thomas F, Dero M, et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab.1993 76:721-727.
98 Flogstad AK, Halse J, Bakke S, et al. Sandostatin-LAR in acromegalic patients: long-termtreatment. J Clin Endocrinol Metab.199781:23-28.
99 Davies PH, Stewart SE, Lancranjan L, et al. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol. 199848:311-316.
100 Caron P, Morange-Ramos I, Cogne M, et al. Three year follow up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab.199782:18-22.
101 Turner HE, Vadivale A, Keenan J, et al. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol.199951:275-280.
102方亦斌,岳志健.生长激素受体拮抗剂治疗垂体生长激素腺瘤的研究进展.中国微侵袭神经外科杂志.2006 11：235-236.
103 Newman CB, Melmed S, George A, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab.1998 83:3034-3040.
104 Valenta LJ, Elias AN. Clinical acromegaly with undetectable growth hormone and hyperprolactinemia. J Natl Med Assoc.198779:555,559-560.
105 Acquati S, Pizzocaro A, Tomei G, et al. A comparative evaluation of effectiveness of medical and surgical therapy in patients with macro-prolactinoma. J Neurosurg Sci.200145:65-69.
106 Mortini P, Losa M, Barzaghi R, et al. Results of transsphenoidal surgery in a large series of patients with pituitary adenoma. Neurosurgery 2005 56:1222-1233; discussion 1233.
107 Buchfelder M, Brockmeier S, Fahlbusch R, et al. Recurrence following transsphenoidal surgery for acromegaly. Horm Res.199135:113-118.
108 Baumann G. Acromegaly. Endocrinol Metab Clin.1987 16:685-703.
109 Katznelson L. An update on treatment strategies for acromegaly. Expert Opin Pharmacother.2008 9:2273-2280.
110 Rao-Balakrishna P, Lees C, Roberts M, et al. Value of early postoperative growth hormone assessment in acromegaly surgery. Endocr Abstr.2007 13:217.
111 Del Porto LA, Liubinas SV, Kaye AH. Treatment of persistent and recurrent acromegaly. J Clin Neurosci.2011 18:181-190.
112 Melmed S, Casanueva F, Caravagnini F, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab.2002 87:4054-4058.
113 Freda P, Nuruzzaman A, Reyes C, et al. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-1 levels. J Clin Endocrinol Metab.200489:495-500.
114 Besser G, Burman P, Daly A. Predictors and rates of treatment-resistant tumour growth in acromegaly. Eur J Endocrinol.2005 153:187-193.
115 Krieger M, Couldwell W, Weiss M. Assessment of long term remission of acromegaly following surgery. J Neurosurg.2003 98:719-724.
116陈书达,王坚,金晓等.垂体生长激素腺瘤显微手术治疗52例分析.浙江医学.200224：593-595.
117 Bourdelot A, Coste J, Hazebroucq V, et al. Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly. Eur J Endocrinol.2004 150:763-771.
118 Freda PU, Nuruzzaman AT, Reyes CM, et al. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab.200489:495-500.
119 Vierhapper H, Heinze G, Gessl A, et al. Use of the oral glucose tolerance test to define remission in acromegaly. Metabolism 2003 52:181-185.
120 Feelders RA, Bidlingmaier M, Strasburger CJ, et al. Postoperative evaluation of patients with acromegaly:clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J Clin Endocrinol Metab.2005 90:6480-6489.
121 Barkan AL. Biochemical markers of acromegaly:GH vs. IGF-1. Growth Horm IGF Res.2004 14 Suppl A:S97-100.
122 Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg. 199889:353-358.
123 Trepp R, Stettler C, Zwahlen M, et al. Treatment outcomes and mortality of 94 patients with acromegaly. Acta Neurochir (Wien).2005 147:243-251.
124 Carmichael JD, Bonert VS, Mirocha JM, et al. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab.200994:523-527.
2王曲,王任直,姚勇.垂体生长激素腺瘤的研究及治疗进展.神经疾病与精神卫生.2008 8：158-160.
3雷霆,张华楸,舒凯等.垂体生长激素腺瘤的诊断与治疗.中国现代神经疾病杂志.2005 5：4-7.
4梁丽,李成江.肢端肥大症11例并发症临床分析.中国实用内科杂志.200525：928-929.
5 Cook DM, Ezzat S, Katznelson L, et al. AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. Endocr Pract.2004 10:213-225.
6 Katznelson L, Atkinson JL, Cook DM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly--2011 update:executive summary. Endocr Pract.2011 17:636-646.
7 Chanson P, Salenave S, Kamenicky P, et al. Pituitary tumours:acromegaly. Best Pract Res Clin Endocrinol Metab.2009 10:555-574.
8 Kauppinen-Makelin R, Sane T, Reunanen A, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab.2005 90:4081-4086.
9 Krzentowska-Korek A, Golkowski F, Baldys-Waligorska A, et al. Efficacy and complications of neurosurgical treatment of acromegaly. Pituitary 2011 14:157-162.
10 Hossain B, M. Drake W. Acromegaly. Medicine 2009 37:407-410.
11 Chanson P, Salenave S, Kamenicky P, et al. Best Pract Res Clin Endocrinol Metab. 200923:555-574.
12 Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999 2:29-41.
13 Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas:a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006 91:4769-4775.
14 Schneider HJ, Sievers C, Saller B, et al. High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin Endocrinol (Oxf).200869:432-435.
15 Vasilev V, Daly A, Zacharieva S, et al. Management of acromegaly. F1000 Med Rep.20102:54.
16 Scanarini M, Mingrino S. Pituitary adenoma secreting more than two hormones. Acta Neuropathol 1979 48:67-72.
17 Schatz H, Daun M, Leicht R, et al. Immunohistochemical examination of pituitary adenomas. Hormone Res.198521:246-253.
18 Ogo A, Haji M, Natori S, et al. Acromegaly with hyperprolactinemia developed after bilateral adrenalectomy in a patient with Cushing's syndrome due to adrenocortical nodular hyperplasia. Endocr J.199340:17-25.
19 Scacchi M, Cavagnini F. Acromegaly. Pituitary 2006 9:297-303.
20 Sheppard MC. Primary medical therapy for acromegaly. Clin Endocrinol (Oxf). 2003 58:387-399.
21 Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly:a consensus statement. J Clin Endocrinol Metab.200085:526-529.
22 Bonert VS, Melmed S. Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. Nat Clin Pract Endocrinol Metab.20062:408-412.
23 Andersen M, Hagen C, Frystyk J, et al. Development of acromegaly in patients with prolactinomas. Eur J Endocrinol.2003149:17-22.
24 Nabarro JD. Acromegaly. Clin Endocrinol (Oxf).198726:481-512.
25 Ezzat S, Forster MJ, Berchtold P, et al. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore).199473:233-240.
26 Nachtigall L, Delgado A, Swearingen B, et al. Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab.2008 93: 2035-2041.
27 Alexander L, Appleton D, Hall R, et al. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf).1980 12:71-79.
28 Klijn JGM, Lamberts SWJ, de Jong FH, et al. Interrelationships between tumor size, age, plasma growth hormone and incidence of extrasellar extension in acromegalic patients. Acta Endocrinol (Copenh).198095:289-297.
29 Kauppinen-Makelin R, Sane T, Reunanen A, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab.2005 90 4081-4086.
30 Valenta LJ, Elias AN. Clinical acromegaly with undetectable growth hormone and hyperprolactinemia. J Natl Med Assoc.1987 79:555,559-560.
31 Fazio S, Cittadini A, Cuocolo A, et al. Impaired cardiac performance is a distinct feature of uncomplicated acromegaly. J Clin Endocrinol Metab.1994 79:441-446.
32 Colao A, Marzullo P, Ferone D, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab. 200085:3132-3140.
33Grunstein RR, Ho KK, Sullivan CE. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med.1994 121:478-483.
34 Colao A, Marzullo P, Vallone G, et al. Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol (Oxf).199951:611-618.
35 Reid TJ, Post KD, Bruce JN, et al. Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006:acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf).201072:203-208.
36 Serri O, Chik CL, Ur E, et al. Diagnosis and management of hyperprolactinemia. CMAJ.2003 169:575-581.
37 Lania AG, Ferrero S, Pivonello R, et al. Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. J Clin Endocrinol Metab.201095:13-17.
38 Fideleff HL, Boquete HR, Suarez MG, et al. Prolactinoma in children and adolescents. Horm Res.200972:197-205.
39 Melmed S, Braunstein GD, Horvath E, et al. Pathophysiology of acromegaly. Endocr Rev.1983 4:271-290.
40王明栋,马文斌,郭梅等.垂体生长激素腺瘤合并泌乳素腺瘤的临床病理特点及诊断治疗.中国医学科学院学报.2005 27：245-248.
41 Maheshwari HG, et al. Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma. J Clin Endocrinol Metab.2000 85:3409-3416.
42 Scheithauer BW, et al. Pathology of excessive production of growth hormone. Clin Endocrinol Metab.1986 15:655-681.
43 Clemmons DR, Van Wyk JJ, Ridgway EC, et al. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med.1979301:1138-1142.
44 Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-1/ somatomedin-C in acromegaly:correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab.198867:69-73.
45 Winer LM, Shaw MA, Baumann G. Basal plasma growth hormone levels in man: new evidence for rhythmicity of growth hormone secretion. J Clin Endocrinol Metab.199070:1678-1686.
46 Freda PU, Post KD, Powell JS, et al. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab.199883:3808-3816.
47 Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management:an update. J Clin Endocrinol Metab.200994:1509-1517.
48 Kreutzer J, Vance ML, Lopes MB, et al. Surgical management of GH- secreting pituitary adenomas:an outcome study using modern remission criteria. J Clin Endocrinol Metab.2001 86:4072-4077.
49 Biermasz NR, van Dulken H, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab.2000 85: 4596-4602.
50 Swearingen B, Barker FG Ⅱ, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab.199883:3419-3426.
51 Cappabianca P, Cavallo LM, de Divitiis E. Endoscopic endonasal transsphenoidal surgery. Neurosurgery 2004 55:933-940; discussion 940-941.
52 Shimon I, Cohen ZR, Ram Z, et al. Transsphenoidal surgery for acromegaly: endocrinological follow up of 98 patients. Neurosurgery 2001 48:1239-1243.
53 Kreutzer J, Vance ML, Lopes MB, et al. Surgical management of GH-secreting pituitary adenomas:an outcome study using modern remission criteria. J Clin Endocrinol Metab.2001 86:4072-4077.
54 Ahmed S, Elsheikh M, Stratton IM, et al. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf). 199950:561-567.
55 Laws ER, Vance ML, Thapar K. Pituitary surgery for the management of acromegaly. Horm Res.2000 53(Suppl 3):71-75.
56 Fahlbusch R, Keller B, Ganslandt O, et al. Transsphenoidal surgery in acromegaly investigated by intraoperative high-field magnetic resonance imaging. Eur J Endocrinol.2005 153:239-248.
57 Melmed S. Medical progress:acromegaly. N Engl J Med.2006 355:2558-2573.
58 Fahlbusch R, Keller B, Ganslandt O, et al. Transsphenoidal surgery in acromegaly investigated by intraoperative high-field magnetic resonance imaging. Eur J Endocrinol.2005 153:239-248.
59 Schwartz TH, Stieg PE, Anand VK. Endoscopic transsphenoidal pituitary surgery with intraoperative magnetic resonance imaging. Neurosurgery 2006 58(1 Suppl):ONS 44-51.
60 Jho HD. Endoscopic transsphenoidal surgery. J Neurooncol.200154:187-195.
61 Swearingen B, Barker FG Ⅱ, Katznelson L, et al. Longterm mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab.199883:3419-3426.
62 Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab.2004 89:667-674.
63 Dimaraki EV, Jaffe CA, DeMott-Friberg R, et al. Acromegaly with apparently normal GH secretion:implications for diagnosis and follow-up. J Clin Endocrinol Metab.2002 87:3537-3542.
64 Gittoes NJ, Sheppard MC, Johnson AP, et al. Outcome of surgery for acromegaly-the experience of a dedicated pituitary surgeon. QJM.1999 92:741-745.
65 Clayton RN. How many surgeons to operate on acromegalic patients? Clin Endocrinol (Oxf).199950:557-559.
66 Clayton RN, Stewart PM, Shalet SM, et al. Pituitary surgery for acromegaly: should be done by specialists. BMJ.1999319:588-589.
67 Ciric I, Ragin A, Baumgartner C, et al. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 1997 40:225-236.
68 Colao A, Ferone D, Lastoria S, et al. Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab.199681:2356-2362.
69 Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly:results of a multicenter trial in 103 patients- a clinical research center study. J Clin Endocrinol Metab.199580:2768-2775.
70 Ben-Shlomo A, Melmed S. Clinical review 154:the role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab. 2003 88:963-968.
71 Jho HD. Endoscopic transsphenoidal surgery. J Neurooncol.2001 54:187-195.
72 Cappabianca P, Cavallo LM, Colao A, et al. Endoscopic endonasal transsphenoidal approach:outcome analysis of 100 consecutive procedures. Minim Invasive Neurosurg.200245:193-200.
73 Cappabianca P, de Divitiis E. Image guided endoscopic transnasal removal of recurrent pituitary adenomas. Neurosurgery 2003 52:483-484.
74 Bohinski RJ, Warnick RE, Gaskill-Shipley MF, et al. Intraoperative magnetic resonance imaging to determine the extent of resection of pituitary macroadenomas during transsphenoidal microsurgery. Neurosurgery 2001 49: 1133-1143.
75 Fahlbusch R, Ganslandt O, Buchfelder M, et al. Intraoperative magnetic resonance imaging during transsphenoidal surgery. J Neurosurg.200195:381-390.
76 Kreutzer J, Vance ML, Lopes M.B, et al. Surgical management of GH-secreting pituitary adenomas:an outcome study using modern remission criteria. J Clin Endocrinol Metab.2001 86:4072-4077.
77 Shimon I., Cohen Z.R., Ram Z, et al. Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery 2001 48:1239-1243; discussion 1244-1245.
78 Jenkins PJ, Bates P, Carson MN, et al. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-1 in patients with acromegaly. J Clin Endocrinol Metab.200691:1239-1245.
79顾昌伟,孙青芳,卞留贯.垂体生长激素腺瘤治疗现状及预后分析.中国微侵袭神经外科杂志.2008 13：90-93.
80 Barkan AL, Halasz I, Dornfeld KJ et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor 1 in patients with acromegaly. J Clin Endocrinol Metab.199782:3187-3191.
81 Biermasz NR, van Dulken H, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab.200085:2476-2482.
82 Barrande G, Pittino-Lungo M, Coste J et al. Hormonal and metabolic effects of radiotherapy in acromegaly:long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab.200085:3779-3785.
83 Brada M, Burchell L, Ashley S et al. The incidence of cerebrovascular accidents in patients with pituitary adenoma. Int J Radiat Oncol Biol Phys.1999 45: 693-698.
84 Mahmoud-Ahmed AS, Suh JH, Mayberg MR. Gamma knife radiosurgery in the management of patients with acromegaly:a review. Pituitary 20014:223-230.
85 Attanasio R, Epaminonda P, Motti E, et al. Gamma-knife radiosurgery in acromegaly:a 4-year follow-up study. J Clin Endocrinol Metab.2003 88: 3105-3112.
86 Castinetti F, Taieb D, Kuhn JM, et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly:correlation with initial hypersecretion. J Clin Endocrinol Metab.200590:4483-4488.
87毕智勇,于春江.肢端肥大症的治疗进展.国外医学神经病学神经外科学分册.2004 31：159-163.
88王志勇,雷霆.肢端肥大症的综合治疗.实用医学杂志.2006 22：1467-1468.
89 Jaffe, CA, Barkan, A.L. Treatment of acromegaly with dopamine agonists. Endocrinol. Metab. Clin. North Am.1992 21:713-735.
90 Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly:a study in 64 patients. J Clin Endocrinol Metab.199883:374-378.
91张正善,丁学华.垂体生长激素腺瘤的治疗进展.中国微侵袭神经外科杂志.2005 10：233-235.
92 Vance, M.L.,Harris, A.G. Longterm treatment of 189 acromegalic patients with the somatostatin analog octreotide. Arch. Intern. Med.1991 151:1573-1578.
93 Newman, CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly:results of a multicenter trial in 103 patients- a clinical research center study. J Clin Endocrinol Metab.1993 80:2768-2775.
94 Grass P, Marbach P, Bruns C, et al. Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly:pharmacokinetic and pharmacodynamic relationships. Metabolism 1996 45:27-30.
95 Stewart, PM, Kane KF, Stewart SE, et al. Depot long-acting somatostatin analog (Sandostatin LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab.1995 80:3267-3272.
96 Lancranjan I, Atkinson AB. Results of a European multicentre study with sandostatin LAR in acromegalic patients. Pituitary 1999 1:105-114.
97 Heron I, Thomas F, Dero M, et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab.1993 76:721-727.
98 Flogstad AK, Halse J, Bakke S, et al. Sandostatin-LAR in acromegalic patients: long-termtreatment. J Clin Endocrinol Metab.199781:23-28.
99 Davies PH, Stewart SE, Lancranjan L, et al. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol. 199848:311-316.
100 Caron P, Morange-Ramos I, Cogne M, et al. Three year follow up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab.199782:18-22.
101 Turner HE, Vadivale A, Keenan J, et al. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol.199951:275-280.
102方亦斌,岳志健.生长激素受体拮抗剂治疗垂体生长激素腺瘤的研究进展.中国微侵袭神经外科杂志.2006 11：235-236.
103 Newman CB, Melmed S, George A, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab.1998 83:3034-3040.
104 Valenta LJ, Elias AN. Clinical acromegaly with undetectable growth hormone and hyperprolactinemia. J Natl Med Assoc.198779:555,559-560.
105 Acquati S, Pizzocaro A, Tomei G, et al. A comparative evaluation of effectiveness of medical and surgical therapy in patients with macro-prolactinoma. J Neurosurg Sci.200145:65-69.
106 Mortini P, Losa M, Barzaghi R, et al. Results of transsphenoidal surgery in a large series of patients with pituitary adenoma. Neurosurgery 2005 56:1222-1233; discussion 1233.
107 Buchfelder M, Brockmeier S, Fahlbusch R, et al. Recurrence following transsphenoidal surgery for acromegaly. Horm Res.199135:113-118.
108 Baumann G. Acromegaly. Endocrinol Metab Clin.1987 16:685-703.
109 Katznelson L. An update on treatment strategies for acromegaly. Expert Opin Pharmacother.2008 9:2273-2280.
110 Rao-Balakrishna P, Lees C, Roberts M, et al. Value of early postoperative growth hormone assessment in acromegaly surgery. Endocr Abstr.2007 13:217.
111 Del Porto LA, Liubinas SV, Kaye AH. Treatment of persistent and recurrent acromegaly. J Clin Neurosci.2011 18:181-190.
112 Melmed S, Casanueva F, Caravagnini F, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab.2002 87:4054-4058.
113 Freda P, Nuruzzaman A, Reyes C, et al. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-1 levels. J Clin Endocrinol Metab.200489:495-500.
114 Besser G, Burman P, Daly A. Predictors and rates of treatment-resistant tumour growth in acromegaly. Eur J Endocrinol.2005 153:187-193.
115 Krieger M, Couldwell W, Weiss M. Assessment of long term remission of acromegaly following surgery. J Neurosurg.2003 98:719-724.
116陈书达,王坚,金晓等.垂体生长激素腺瘤显微手术治疗52例分析.浙江医学.200224：593-595.
117 Bourdelot A, Coste J, Hazebroucq V, et al. Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly. Eur J Endocrinol.2004 150:763-771.
118 Freda PU, Nuruzzaman AT, Reyes CM, et al. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab.200489:495-500.
119 Vierhapper H, Heinze G, Gessl A, et al. Use of the oral glucose tolerance test to define remission in acromegaly. Metabolism 2003 52:181-185.
120 Feelders RA, Bidlingmaier M, Strasburger CJ, et al. Postoperative evaluation of patients with acromegaly:clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J Clin Endocrinol Metab.2005 90:6480-6489.
121 Barkan AL. Biochemical markers of acromegaly:GH vs. IGF-1. Growth Horm IGF Res.2004 14 Suppl A:S97-100.
122 Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg. 199889:353-358.
123 Trepp R, Stettler C, Zwahlen M, et al. Treatment outcomes and mortality of 94 patients with acromegaly. Acta Neurochir (Wien).2005 147:243-251.
124 Carmichael JD, Bonert VS, Mirocha JM, et al. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab.200994:523-527.